MedPlus Health: Private Label Makes Up 21.4% of Revenue
MEDPLUS MedPlus Health Services (NSE : MEDPLUS) is a Hyderabad-based pharmacy retailer. It operates 5,642 stores across 13 states, covering more than 860 cities and towns. The network uses a cluster model, building density in existing markets first. Of the total stores, 849 are franchisee-operated. What happened: In Q2 FY27, consolidated revenue reached Rs 2,037.1 crore, up 21.3% year on year. Gross margin was 25.1%. EBITDA was Rs 98.1 crore with a 4.8% margin. Stores older than 12 months contributed 93% of pharmacy revenue at an 11.7% store-level EBITDA margin. Private label sales were 21.4% of revenue. The diagnostics division generated Rs 41.1 crore in revenue at a 23.8% operating margin. Why it matters: MedPlus added 166 net stores in Q2 FY27, with 101 beyond Tier 1 cities. Private label products carry better margins than branded medicines. The company had 2.16 lakh active health subscription plans as of September 2026. The 29% of stores open under 24 months are a source of future earnings as they mature to the 11.7% store-level EBITDA margin of the older network. What I am watching: Whether consolidated EBITDA margins expand as the younger stores mature. MedPlus targets 800 net store additions in FY27 and had added 312 by end of H1. Store-level returns at the new locations will show whether the expansion adds or dilutes value. My stance: MedPlus trades at 35.2 times earnings, below its three-year historical median of 70.2 times and the industry median of 45.2 times. ROCE is 24.2%, well above the industry average of 11.5%. The valuation discount to its own history and to peers makes it the cheaper of the two pharmacy stocks covered here. I do not hold a position in MedPlus Health Services at the time of writing. This is not investment advice.



















